Hua Medicine
02552
Company Profile
Business description
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.
Contact
Lane 36, Xuelin Road
Hua Medicine, Building 2
Pudong New Area
Shanghai201203
CHNT: +86 2138101800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2024
Employees
172
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,515.20 | 3.70 | -0.04% |
CAC 40 | 7,226.98 | 199.90 | -2.69% |
DAX 40 | 19,033.64 | 414.96 | -2.13% |
Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
FTSE 100 | 8,025.77 | 99.42 | -1.22% |
HKSE | 19,846.88 | 580.05 | -2.84% |
NASDAQ | 19,281.40 | 17.36 | -0.09% |
Nikkei 225 | 39,376.09 | 157.23 | -0.40% |
NZX 50 Index | 12,684.56 | 64.80 | -0.51% |
S&P 500 | 5,983.99 | 17.36 | -0.29% |
S&P/ASX 200 | 8,255.60 | 10.60 | -0.13% |
SSE Composite Index | 3,421.97 | 48.10 | -1.39% |